company background image
ARWR logo

Arrowhead Pharmaceuticals NasdaqGS:ARWR Stock Report

Last Price

US$28.60

Market Cap

US$3.6b

7D

1.3%

1Y

17.1%

Updated

28 Mar, 2024

Data

Company Financials +

Arrowhead Pharmaceuticals, Inc.

NasdaqGS:ARWR Stock Report

Market Cap: US$3.6b

ARWR Stock Overview

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.

ARWR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Arrowhead Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Arrowhead Pharmaceuticals
Historical stock prices
Current Share PriceUS$28.60
52 Week HighUS$42.48
52 Week LowUS$20.67
Beta0.72
1 Month Change-8.23%
3 Month Change-6.54%
1 Year Change17.07%
3 Year Change-57.36%
5 Year Change47.80%
Change since IPO-45.00%

Recent News & Updates

Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Mar 08
Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Feb 19
Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Recent updates

Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Mar 08
Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Feb 19
Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy

Jan 21

Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now

Dec 25
Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?

Sep 19
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up

Apr 17
Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up

Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now

Mar 10
Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now

A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Jan 24
A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn

Oct 24
We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn

Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities

Sep 12

Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming

Aug 23

Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease

Aug 17

Arrowhead Pharmaceuticals: An RNAi Name To Know

Jul 28

Arrowhead Pharmaceuticals names internal officer as new COO

Jul 20

Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs

Jul 05

Arrowhead Pharma: We Can Afford To Wait For More Proof

Jun 28

Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth

Jun 18
Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth

Arrowhead Pharma: Know Pros' Calcs For Coming Stock Prices

Apr 14

Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 46%?

Feb 08
Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 46%?

Arrowhead: 2021 Was A Struggle Valuation Wise - Things May Get Worse In 2022

Jan 26

Accumulate Arrowhead For Its RNAi Pipeline

Jan 17

Johnson & Johnson's JNJ-3989 News Could Propel Arrowhead Stock To New All-Time Highs

Nov 03

Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 34%?

Oct 09
Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 34%?

The Partnership Effect: Arrowhead Forges Its Future

Aug 27

Shareholder Returns

ARWRUS BiotechsUS Market
7D1.3%0.9%0.4%
1Y17.1%10.3%28.8%

Return vs Industry: ARWR exceeded the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: ARWR underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is ARWR's price volatile compared to industry and market?
ARWR volatility
ARWR Average Weekly Movement9.6%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: ARWR's share price has been volatile over the past 3 months.

Volatility Over Time: ARWR's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1989525Chris Anzalonehttps://arrowheadpharma.com

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases.

Arrowhead Pharmaceuticals, Inc. Fundamentals Summary

How do Arrowhead Pharmaceuticals's earnings and revenue compare to its market cap?
ARWR fundamental statistics
Market capUS$3.56b
Earnings (TTM)-US$296.81m
Revenue (TTM)US$181.74m

19.5x

P/S Ratio

-11.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARWR income statement (TTM)
RevenueUS$181.74m
Cost of RevenueUS$0
Gross ProfitUS$181.74m
Other ExpensesUS$478.55m
Earnings-US$296.81m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.40
Gross Margin100.00%
Net Profit Margin-163.32%
Debt/Equity Ratio157.6%

How did ARWR perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.